• Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe
• The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio
• Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential
• The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its R&D programs

Lexaria Bioscience (NASDAQ: LEXX) is a global innovator and biotechnology company focused on developing technology that enhances the bioavailability of multiple fat-soluble active molecules and active pharmaceutical ingredients (“APIs”). The company’s flagship technology is the patented DehydraTECH(TM) drug delivery technology, which combines fat-soluble (lipophilic) molecules or APIs with specific fatty acids and carrier compounds, improving properties such as the speed of onset, brain absorption, and bioavailability.

The company has continuously worked on DehydraTECH since 2014, with these efforts expanding the technology’s potential area of impact, both geographically and by sector. For instance, thanks to its extensive research and development (“R&D”), the company has identified viable commercial applications of DehydraTECH across several segments, including, but not limited to, cannabidiol (“CBD”) for hypertension and heart disease, treatments for dementia, hormone treatments, reduced risk non-combusted nicotine, and more (https://ibn.fm/WEejV).

“Because of the applicability of DehydraTECH to many market sectors across the globe, we have taken the necessary steps to protect that intellectual property internationally,” the company says in its 2022 Form 10-K annual report (https://ibn.fm/eE5hR). Accordingly, Lexaria has filed tens of patent applications in multiple jurisdictions with the highest commercial potential.

Lexaria believes that the successful granting of more of those applications could lead to material increases in shareholder value. The company also holds that its ability to generate meaningful license revenue from its intellectual property may increase should the remaining patent applications become granted patents.

Since 2014, Lexaria’s efforts to protect its intellectual property internationally have been paying off, with the company receiving granted patents in multiple jurisdictions. Recently, the company announced the receipt of two new patents granted by the Canadian Intellectual Property Office (“CIPO”), increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio (https://ibn.fm/IkcMG).

More specifically, the company received a new Canadian patent under its Patent Family #3: “Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents.” Registered as patent #2,984,917 on CIPO’s Canadian Patent Database, the new patent recognizes Lexaria’s innovations in delivering fat-based (lipophilic) active molecules and active drugs suspended in water-based formats.

Lexaria also received Canadian patent #3,111,082 under its Patent Family #14. Titled “Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof,” the patent covers the company’s innovations that infuse tobacco leaves directly with active drugs or active molecules like nicotine with or without cannabinoids for such potential applications as treating nicotine addictions.

The two new patents increase Lexaria’s Canadian patent portfolio to five granted patents, following the staggered receipts of three Canadian patents over a span of less than a year. Last December, the company announced the receipt of the first granted patent in Canada, registered as patent #3,093,414 on CIPO’s database. The patent, which falls in the company’s Patent Family #6, is entitled “Transdermal and/or Dermal Delivery Of Lipophilic Active Agents.” It recognizes and protects Lexaria’s improved compositions and methods for transdermal and dermal delivery of cannabinoids such as tetrahydrocannabinol (“THC”) and CBD (https://ibn.fm/AKc5a).

In June, Lexaria announced that it had received two additional Canadian patents. The first patent is under Patent Family #1: “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof,” while the second is under Patent Family #8: “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://ibn.fm/aUlIH).

“Our current patent portfolio includes patent family applications or grants pertaining to our method of improving bioavailability and taste, and the use of DehydraTECH as a delivery platform for a wide variety of APIs including, but not limited to, fat-soluble vitamins; anti-viral drugs; phosphodiesterase inhibitors; human hormones; regulated cannabinoids; and nicotine and its analogs,” Lexaria explains in its most recent Form 10-Q quarterly report (https://ibn.fm/gzcor). “The company has patents issued in the United States, Australia, Europe, India, Mexico, Canada, and Japan.”

Still, the company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio. Lexaria is also filing new patent applications for discoveries that arise from its R&D programs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

The 3rd Investigator Initiated Trials Summit will be held on November 13-14, 2023 in Philadelphia. The DGE event is focused on exploring the most lucrative ways for reviewing, selecting, and funding research investigators. Researchers, medical officers, health and pharma executives and companies can harness the reach and network of the DGE platform to connect with industry stalwarts and discuss vital issues on how they effectively manage IITs.

The speakers will offer important insights on ways to leverage the new methods for new indications, label expansion and potential publications. The conference aims to create a bridge between pharma suppliers and sponsors who are providing vital data and real-world evidence while remaining compliant.

The event is organized by Dynamic Global Events (“DGE”), the leading life science B2B event organizer. This event can be accessed in person and will be streamed live on a trusted interactive platform. Thought leaders, pharma professionals, researchers and leading pharma from across the spectrum will attend to discuss informative topics and form networking connections.

Key Topics Of Discussion:

• Ways to manage costs, design contracts, and budgetary negotiations
• Gear up resources to reach out to remote and small-population segments
• Training and maintaining the best team to improve compliance and communications for the research trials
• Discussing the role of MSLs in IITs
• Discussing Collaborative Studies vs. Traditional IITs/IIRs
• Securing operational support and valuing the well-trained admins

To know more, please visit https://ibn.fm/AOeXP

• Clene’s wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”)
• The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8
• Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on a mission to transform the treatment of neurodegenerative diseases, recently announced that its wholly-owned subsidiary Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”). The grant will support an Expanded Access Protocol (“EAP”) for Clene’s investigational drug, CNM-Au8(R), for amyotrophic lateral sclerosis (“ALS”). The grant is supported by the National Institute of Health (“NIH”) grant U01NS136023 (https://ibn.fm/03fnZ).

An EAP, also called “Compassionate Use,” is an FDA-regulated pathway that allows people with serious and life-threatening diseases to access investigational drugs that have not yet been approved by the US Food and Drug Administration (“FDA”). In addition to the EAP, Clene plans to continue its current ongoing ALS EAP programs, which have enrolled more than 200 participants since 2019.

Jinsy A. Andrews, MD, MSc, FAAN, an associate professor of neurology in the Division of Neuromuscular Medicine and director of Neuromuscular Clinical Trials at Columbia University, said this EAP study will give ALS patients who don’t meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8 as a novel investigational therapy through this EAP program. “Programs like this help to advance research and much-needed innovation in ALS,” he added.

In addition to Andrews, the EAP study will be led by Eric Anderson, MD, PhD, MBA, FAAN, of Synapticure, and Benjamin Greenberg, MD, MHS, FAAN, Head of Medical of Clene. The EAP will provide eligible people living with ALS to work with clinicians to access CNM-Au8 – with access available across all 50 states, including remote and rural areas, through Synapticure’s telemedicine neurology clinic and nationwide clinics. The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8.

“Clene has demonstrated evidence of consistent safety and improved survival for CNM-Au8 across a broad ALS population in two independent Phase 2 trials and an ongoing EAP with up to 3.8 years of follow-up,” Greenberg stated. “This new EAP provides access to CNM-Au8 for more people living with ALS and enables the collection of survival, safety, and biomarker data in a population not studied in clinical trials. These data can help provide confirmatory support for the existing trial data Clene has gathered in its clinical trials.”

According to research conducted by Clene, ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide. The life expectancy of diagnosed patients typically ranges from three to five years – with a high market need for treatments that affect daily function and survival. Coupled with a critical unmet need for therapeutic interventions, the EAP will provide additional support to people with ALS who did not have access to these types of drugs in the past.

“We are truly excited to be a part of this grant with Clene and Columbia and to support people living with ALS by providing access to treatments that could meaningfully impact the course of their disease,” Anderson said. “We are grateful to NINDS for recognizing how a virtual platform like Synapticure can provide expanded access programs in a remote capacity. It will allow us to reach people living with ALS across the US who have not previously had access to investigational medicines, like CNM-Au8.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• XESP, a market disruptor for B2B companies, is offering businesses a way to create digital customer interactions that pay off
• Powered by its Digital Engagement Engine(TM), XESP is helping businesses avoid wastefulness while also achieving growth through its four-pronged approach
• With its proprietary smart tools and technologies, the company offers value to its clients, allowing them to reach their customers at the right moment- when they need the client’s product or service
• XESP is completely focused on the global customer engagement solutions market, projected to hit $32.2 billion in revenue by 2027, while also asserting itself as a leader in its segment

Electronic Servitor Publication Network (OTCQB: XESP), a market disruptor for B2B companies using cutting-edge data analysis and smart technology, is staying ahead of the curve, leveraging new and more efficient ways for businesses to drive engagement, reach bigger audiences, and build authority and credibility in their spaces. Its approach has earned it recognition from growth-focused companies and from investors.

XESP has been quick to identify inefficiencies and then provide viable and effective solutions. By focusing on eliminating wastefulness, driving growth, and helping modern businesses thrive in the evolving digital space, the company is asserting its position as a technology leader. Its revolutionary Digital Engagement Engine(TM) has been integral in achieving this objective and XESP management expects that technology will be the primary driver for the company’s continued growth.

“With our Digital Engagement Engine(TM), it’s not just about throwing everything you’ve got against the wall and hoping something sticks,” notes the company’s official communication (https://ibn.fm/X0eFT).

Instead, XESP adopts a four-pronged approach to solving the problem – data analysis, identification tech stack, tailored content, and precision delivery. With its proprietary smart tools and technologies, the company can flawlessly acquire data, allowing it to identify even the narrowest of niches for businesses’ target markets. With this information, the Digital Engagement Engine(TM) helps clients create content that meets the customers’ exact needs at the right moment when they need the client’s product or service.

The flexibility and overall potential of the Digital Engagement Engine(TM) have given XESP a significant upper hand in the digital activation and engagement space. It has allowed the company to effectively promote meaningful communication between clients and their audiences, allowing for a “laser-focused approach that makes every customer feel like you’re talking directly to them.”

Given the effectiveness of XESP’s Digital Engagement Engine(TM), businesses can now easily build new customer relationships. More importantly, they can develop real connections with their target markets, allowing for higher conversions, sales, customer retention, and overall business growth. The global customer engagement solutions market is projected to hit $32.2 billion in revenue by 2027, posting a CAGR of 10.8% from 2022. XESP looks to tap into this growth while also asserting itself as a leader in its segment.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Prospera Energy recently provided an update on the second phase of the company’s restructuring plan
• With its initial five horizontal wells and incremental crude production tracking ahead of expectations, Prospera have announced plans to continue their second phase beyond its initially mooted ten well program
• The company has now announced that it will proceed with a low dilutive capital raise of $3 million, with proceeds destined to fund the exploration company’s ongoing capex

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada, recently provided the market with an update on the second phase of its restructuring program. Boasting a business model centered around optimizing hydrocarbon recovery from legacy fields through innovative production practices and seeking to exploit the over 42,000 cumulative acres of territory across the company’s core assets, Prospera designed its second phase around drilling 10 horizontal well locations at its Cuthbert and Hearty Hills properties.

The second phase of Prospera Energy’s program has quickly advanced beyond initial expectations, with the company having already successfully drilled five horizontal wells of its multi-well infill horizontal development program (https://ibn.fm/Najtv). Prospera further revealed that with two of its horizontal wells having already commenced production and the three additional horizontal wells set to commence production in subsequent weeks – the latter due to the firm’s desire to bring the wells on in a gentle way to accommodate the steady flow of the heavier viscous oil, Prospera’s gross production levels should touch 1,500 bpd by October (from 800 bpd the previous month).

With the company’s crude production tracking well ahead of initial projections and in a bid to capitalize on the current high Western Canadian Select price of $90 plus per barrel, Prospera have recently announced their intention to continue beyond their initially mooted ten well program, with the horizontal infill drilling program set to resume over the next few weeks. To finance their ongoing endeavors and upcoming capital expenditure plans, Prospera have announced a low dilutive capital raise with the company seeking to unveil a significant boost to their production capacity in the near future.

As such, Prospera Energy have announced that they will be undertaking a non-brokered private debt placement, seeking to raise gross proceeds of up to $3,000,000. Investors will be offered an interest rate of 14% per annum, with interest payments to be made quarterly for a term duration of 2 years. Separately and in addition to a quarterly coupon, debt holders will be in line to receive one common share per dollar of principal advanced at the time of investment – a measure designed to align debt holders’ interests with Prospera Energy’s significant growth ambitions. Nonetheless and in a nod to the company’s conservative capital structure program, Prospera have continued to focus on minimal dilution financing options, with the mooted capital raise plan ultimately leading to less than 1% equity dilution to the company.

Going forward and in 2023, Prospera’s corporate redevelopment strategy will continue its full-scale enhanced oil recovery (“EOR”) strategy, forecast to enhance recovery rates achieved in the ongoing second phase of the program by upwards of 10%. Additionally, the company intends to continue its acquisition strategy to diversify its product mix – with a goal of attaining a production profile comprised of 50% light oil, 40% heavy oil and 10% gas. With record growth in 2023 driving Prospera Energy’s net present value to new historical highs, the company’s designs on achieving an incremental production rate of 2,253 BPD in 2024 coupled with rapidly rising crude prices have set the stage for the company to achieve new highs in the months ahead.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

Social media marketers, businesses, company executives, influencers and marketing heads, are invited to attend the Social Media Strategies Summit for Senior Level Marketing Professionals, October 26-27, 2023. This two-day virtual event will be attended by social media stalwarts who will share their time-tested strategies for conducting successful social media campaigns for organizations. The event will be preceded by an optional workshop on October 25, 2023, conducted by an experienced trainer.

SMSS is a leading organizer of social media conferences and events that cater to a wide spectrum of organizations and enterprises. They offer a robust networking and business platform where peers can connect and learn from the invaluable social media tips offered by the top social media players, digital marketers, and data analysts.

The event commences on October 26 with welcome remarks from the Summit Emcee, Elena Routsavakis, Owner, Chief Igniter, Boom Strategies. This will be followed by interactive sessions on how to create content that educates and entertains the audience. Tips on creating top video content creation strategies will be discussed by the thought leaders.

Social media heads will also discuss vital elements of social media governance while applying strategies for brand success. Thought leaders will offer creative ideas and insights on ways to leverage the new AI trends namely ChatGPT for social media campaigns. Draw insights from cross-industry case studies to gauge the best opportunities for better online presence.

Experts will also throw light on drawing the maximum output regardless of the size of the team or budget. Speakers will also talk about extracting meaningful data from social media analysis. Budding businesses and young marketers can learn how creators and influencers can co-create and support each other on social media platforms. Speaker-led round table discussions on strategies for several social media platforms will follow.

To know more, please visit https://ibn.fm/WVL3C

• Canadian mineral explorer Appia Rare Earths & Uranium is working to develop sources for rare earth elements (“REEs”) vital to modern computer technologies, spanning sites in Canada and Brazil
• The company’s 17,551-hectare (43,369.5 acres, or 67.8 square miles) PCH Ionic Clay Project in Brazil has completed assay work on the initial 17 drill holes in the “Target IV” section of the project, finding REE mineralization in all of them to a depth of 13 meters
• With 147 holes drilled at the Brazilian site, Appia is optimistic that the high-grade values observed near the surface could lead to a mining and refining process that is more environmentally sustainable and economically efficient
• Beyond Brazil, the company is also exploring for REEs in mineral rich areas of Saskatchewan and Ontario, Canada, recently completing an NI43-101 technical report on the Saskatchewan site
• Appia’s exploration is part of a renewed drive in the industry to develop REE supply chains that are not dependent on China’s dominant market presence

Mineral explorer Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) is making significant progress in its Brazilian rare earth reverse circulation (“RC”) drilling campaign, reporting overall weighted average grades of total rare earth oxides (“TREOs”) that are comparable or superior to other well-known international deposits.

In an Oct. 16 news release, the Company stated that it has assayed the first 17 of 147 drill holes that have been completed at its PCH Ionic Clay Project in Goias State, Brazil. 100 percent of the assays confirm rare earth element (“REE”) mineralization, demonstrating outstanding measures of Magnet Rare Earth Oxides (“MREOs”) and Heavy Rare Earth Oxides (“HREOs”) to an average depth of 13 meters from the surface.

“It’s very exciting to witness the PCH Ionic Clay project’s potential increasing through this Phase 1 drilling campaign,” Appia CEO Tom Drivas stated (https://ibn.fm/kOmrR). “Ionic Clay Rare Earths Deposits are usually found within the top 10-20m from surface; they are easier to mine, more environmentally friendly because they contain low or no radioactivity; exhibit simpler metallurgy (and are) therefore easier and cheaper to process; and contain good amounts of both the very valuable heavy and light magnet rare earths that are in high demand for cleaner electrification and use in a large number of high tech applications.”

Geology Manager Carlos Bastos, a Brazilian qualified person, added, “We have identified high-grade values that are exceptional in terms of both width and grades.”

The PCH Ionic Clay Project in Brazil’s Goiás State covers 17,551 hectares (43,369.5 acres, or 67.8 square miles), with the initial drill results all reported in the site’s “Target IV.” The positive results of the geochemical exploration analysis indicate the potential for mining REEs there, including erbium, cerium, dysprosium, praseodymium, neodymium, samarium, and others.

Over the past decade, rare earth elements have gained significant prominence due to their pivotal role in modern computer-based technologies. These elements, particularly high-tech magnets, are integral components in a wide array of products, spanning from computer hard drives and electric vehicle batteries to crucial engine components in advanced aircraft like the F-35 fighter jets.

The REE supply chain is largely controlled by industry within the People’s Republic of China and, therefore, that country’s governmental policies, leading to a renewed drive to source and refine REEs in Western nations, including the Americas. Appia’s Brazilian project represents an exciting development amid that push for Western REE sourcing.

The Company holds the right to acquire up to a 70 percent interest in the project.

Appia also 38,522 contiguous hectares (95,191 acres) of high-grade mineralization in northern Saskatchewan, Canada, that the company is exploring for REE potential, and recently completed an NI43-101 technical report on the property (https://ibn.fm/rPA9I). And the company has a 100 percent interest in 12,545 hectares (31,000 acres) with REE deposits in Ontario, Canada, as well as four uranium claim blocks in Northern Saskatchewan it may use for exploration.

The company is working to protect shareholders’ interests as it continues its exploration activities, reporting earlier this month that Appia “is unaware of any information relating to the Company that would account for the significant volume of trading and drop in the price of the Company’s shares that occurred on September 29, 2023,” for a market clarification (https://ibn.fm/ep2XI).

Appia’s most recent report states it has 130.5 million common shares outstanding, and 143.3 million shares fully diluted.

For more information, visit the company’s website at www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

• Fr8Tech has witnessed a rise in carrier capacity, reporting a 60.8% year-over-year increase in August 2023 carrier capacity levels compared to August 2022
• The average capacity levels through August rose 55.7% year-to-date
• Luisa Lopez, Fr8Tech COO, attributed this growth to the company’s commitment to delivering quality services even during periods of downtime and securing high-quality carrier capacity
• Fr8Tech also announced that Fr8App recently completed an integration with Geotab’s open API
• The integration now allows Fr8App users to experience easy and precise tracking and monitoring of shipments

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a North American transportation logistics technology company offering solutions that optimize logistics, reduce transportation costs, and improve experiences and efficiency for shippers and carriers in the U.S.-Mexico-Canada Agreement (“USMCA”) member countries.

The company has developed and is commercializing Fr8App, a custom-built freight-matching platform offering a real-time portal for B2B cross-border shipping and domestic shipping; Fr8Fleet, a digital platform that lets enterprise customers handle dedicated truck services, capacity, and operation; and Fr8Now, a digital freight-matching platform offering less-than-truckload (“LTL”) services in Mexico.

Since launching early last year, Fr8Fleet has secured new and existing Fr8App customers, including leading manufacturers in Mexico, who joined the platform as shippers (https://ibn.fm/jD0kI). Commensurate with the rise in shippers, Fr8Tech has also witnessed a rise in carrier capacity, reporting a record number of active carriers in its Fr8Fleet brand at the end of August, according to a September 5 news release (https://ibn.fm/djeDq).

Fr8Tech announced that its carrier capacity increased by 60.8% in August 2023 compared to August 2022. Moreover, the average capacity through August rose 55.7% year-to-date (“YTD”). This growth is indicative that the company is “getting back on track,” according to Fr8Tech COO Luisa Lopez, especially because it follows a challenging first quarter of the year, a period in which the company “had to cycle through some underperforming carriers.” Still, the company maintained the expected high level of quality of its services, and this commitment, coupled with other interventions, is now paying off in spades.

“An important limitation to our ability to grow the Fr8Fleet brand has been related to securing high-quality carrier capacity, and we have focused on doing just that for some time, and our efforts are starting to bear fruit,” said Fr8Tech COO Luisa Lopez. “We expect to be able to show improvements in recurring monthly revenue from Fr8Fleet through the remainder of the calendar year and into 2024.”

Lopez went on to explain that the company has confirmed the existence of shipper clients in the Mexico domestic market that will enable its Fr8Fleet business unit to continue growing through the remainder of 2023.

“We have been tirelessly working on getting these key large shipper clients on our platform, and we are pleased to announce the corresponding increase in carrier activity on our platform,” continued Lopez. “We need both sides of the platform to make a marketplace, and we continue working toward creating critical mass on both the demand and supply sides of our platform. Our capacity for this segment is up year over year, and we have had steady monthly increases since February 2023, which will start showing up in our results for both this upcoming third quarter and the ones to follow.”

Meanwhile, the company announced that Fr8App recently completed an integration with Geotab’s open application programming interface (“API”), which will lead to a substantial improvement in real-time visibility and efficiency for both shippers and carriers (https://ibn.fm/In8td).

A global leader in connected transportation solutions, Geotab provides vehicle and asset tracking solutions – powered by artificial intelligence (“AI”) and data intelligence – that enable client companies to transform their operations and fleet. Geotab connects to more than 3.6 million vehicles – and growing – and processes over 55 billion data points every day, enabling customers to have safer fleets, increase productivity, make better decisions, and achieve their sustainability goals (https://ibn.fm/r8WRS).

Through the completed integration with Geotab’s open API, Fr8App users can now enjoy the additional features and tools. The integration enables Fr8App users to harness the power of Geotab’s advanced tracking capabilities to experience easy and precise tracking and monitoring of shipments.

“Continuing our journey to become the ultimate connectivity hub, we’re seamlessly integrating with the industry’s foremost players across our platform. This strategic integration equips our business partners with the tools needed to optimize their logistics operations in ways they had previously not been able to,” Javier Selgas, CEO of Fr8Tech, said of the integration.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies
• The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care
• By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments
• GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development
• Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may help strengthen GEDi Cube’s AI technology

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (https://ibn.fm/gA9cq).

The combined company brings together renowned leaders across AI and immunotherapy, including Dr. Dybul, who brings decades of global health leadership experience; GEDi Cube CEO Craig Rhodes, the former head of Life Sciences for Europe, the Middle East, and North Africa at NVIDIA; Gregg Alton, former interim CEO of Gilead Sciences; and Dr. Anahid Jewett, Professor and Director of the tumor immunology laboratory at UCLA; just to mention a few.

Once completed, the transaction will result in a combined company in which GEDi Cube will become a wholly-owned subsidiary of Renovaro, rebranding as Renovaro.AI.  GEDi Cube CEO Craig Rhodes will lead Renovaro.ai.

The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an October 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing together two innovative platforms in biotherapeutics and AI, the combined company intends to create comprehensive solutions for early cancer detection, diagnostic insights, and effective targeted immunotherapies. It is the intent of both organizations that Mark Dybul will lead.

“We believe the combination will accelerate our shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics,” wrote Dr. Dybul. In the message, Dr. Dybul provided insights on the news of the definitive agreement and shared the vision for the newly combined company (https://ibn.fm/yCxnp).

According to Dr. Dybul, GEDi Cube and Renovaro Biosciences came together through a shared desire to turbo-charge innovation and efficacy in precision medicine. The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to improve patient outcomes by detecting diseases sooner and matching treatments more precisely based on the individual’s genetic profile.

On its part, GEDi Cube has developed and honed its proprietary AI technology over the past decade. The technology uses differential multi-omics analysis to pinpoint molecular patterns that detect cancer sooner than standard techniques. The analysis searches for patterns across transcriptomics, epigenomics, genomics, among others to identify informative biomarkers. So far, the technology can identify biomarkers for over 12 cancers. GEDi Cube’s AI technology has shown 95% accuracy in detecting cancers earlier by analyzing complex molecular data.

Recently, GEDi Cube joined NVIDIA (NASDAQ: NVDA) Inception, a program that nurtures budding companies by providing access to cutting-edge technology, technical resources, and venture capitalists. As a result of this strategic partnership, GEDi Cube will supplement its proprietary technology with NVIDIA’s advanced medical imaging capabilities to create an algorithm that relies on both the omic and imaging modals (https://ibn.fm/7AFbB). According to Dr. Dybul, this is poised to help GEDi Cube improve diagnostic accuracy further.

Renovaro Biosciences, on its part, has developed an advanced immunotherapy platform focused initially on lethal solid tumor cancers that have seen limited improvements in survival rates. The company uses a patented approach that modifies allogeneic dendritic cells to stimulate anti-tumor immunity specific to a patient’s genetic profile. In pancreatic cancer models, this technology has shown an 80-90% reduction in tumor size.

“As we learned about each technology, it rapidly became apparent that combining Renovaro’s immunotherapies with GEDi Cube’s AI-driven early diagnostic capabilities, its potential to help determine cancers to target for therapy, to monitor the effectiveness of therapy, and even discovering new approaches to treatment could lead to a powerful synergy,” explained Dr. Dybul.

Moreover, GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development, while Renovaro’s data repository, which includes, among others, knowledge about critical aspects of the immune system that relate to how cancers could respond to treatment, could help strengthen GEDi Cube’s AI technology.

Dr. Dybul expressed his optimism about the growth trajectory ahead, highlighting that the combined company intends to launch multiple revenue-generating products beginning in 2024. The AI division plans to launch commercial products for early cancer detection and improved therapy selection in 2024.

The immunotherapy division intends to start Phase 1/2 trials of Renovaro’s lead asset in the second half of 2024. The commencement of the trials is expected to possibly lead to emergency use authorization as soon as the end of 2027 following the results of a Phase 2 clinical trial. Dr. Dybul anticipates that the potential emergency use authorization will transform treatment for cancers with stagnant survival rates like pancreatic cancer.

“United, we believe we can achieve the shared goal of delivering more effective, proactive, and personalized care to the patients who need it,” concluded Dr. Dybul.

For more information, visit the company’s website at www.RenovaroBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis
• The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis
• The study also revealed that the outer skin layers regained their normal appearance
• The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients
• Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis and intends to begin in-vivo animal studies early next year

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical and biotechnology company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological therapeutics, recently announced encouraging results from a preclinical study that suggest the therapeutic potential of the anti-interleukin 17 (“IL-17”) nanosized antibodies (“NanoAbs”) to relieve symptoms of plaque psoriasis (https://ibn.fm/mFsNO).

Plaque psoriasis is the most common psoriasis phenotype, affecting 80-90% of psoriatic patients (https://ibn.fm/oxKF7). It is caused by the excessive proliferation of keratinocytes (skin cells that, by secreting keratin, strengthen the skin, shield against UV penetration, and protect against microbial invasion), “the complex interaction of activated innate and adaptive immune cells (notably dendritic cells and T cells) that infiltrate the skin, and chronic inflammation” (https://ibn.fm/9zmdp). Several cytokines are at the center of the activation and subsequent infiltration of the immune cells; among these, IL-12, IL-17, and IL-23 are currently considered the most important therapeutic targets.

So far, companies like Novartis (NYSE: NVS) and Eli Lilly (NYSE: LLY) have launched biological treatments, primarily monoclonal antibodies (“mAbs”), that target IL-17A, a member of the IL-17 family. On its part, Novartis developed and is commercializing Cosentyx(R), which was approved by the U.S. Food and Drug Administration (“FDA”) in 2015 (https://ibn.fm/cC55Q). As well, the FDA approved Eli Lilly’s Taltz(R) in 2016 (https://ibn.fm/W7cXR). More recently, UCB received European Commission approvals to market BIMZELX(R) for the treatment of adults with active psoriatic arthritis (https://ibn.fm/5hRJs).

“All the above-mentioned antibodies, indicated only for moderate to severe psoriasis patients, are administered by subcutaneous injection for systemic drug distribution and carry risk of considerable side effects. These drugs are also expensive as they require chronic, life-long, bi-weekly injections, each at a cost of several thousand dollars,” explained Scinai in a news release. “Mild psoriasis, which accounts for 50% of plaque psoriatic patients, unfortunately has no safe and affordable biological drug available.”

Having recently signed an exclusive worldwide license agreement for the development and commercialization of a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, starting with psoriasis (https://ibn.fm/0Fh04), Scinai is on a quest to provide safe, effective, and affordable treatment for patients with mild to moderate psoriasis. The company’s preclinical study, ergo, brings it closer to actualizing its vision.

As part of the study, researchers constructed a 3D biological skin model out of a scaffold mounted with various skin cells to generate layers that mimic the structure of human skin and induced it to express plaque psoriasis. They then introduced the anti-IL-17 NanoAbs into the model either subcutaneously or topically to test them as a potential treatment for the condition.

The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers, S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis. Moreover, the study revealed that the stratum corneum (the outer skin layers) regained its normal appearance. These results, the company said, suggest the potential for a highly efficacious, specific, yet safer and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients.

According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis, with more than 8 million of them living in the U.S. (https://ibn.fm/OJI4J). Among these patients, 51.8%, 35.8%, and 12.4% have mild, moderate, and severe disease, respectively, according to a study that sampled patients aged 25 to 64 years (https://ibn.fm/YEIbg). This means that more than 80% of patients with psoriasis present with mild to moderate severity (https://ibn.fm/jTMsU), with the majority having mild illness, yet the treatments are geared toward the minority.

Scinai aims to tap into this huge underserved market, providing efficacious psoriasis treatment that is designed to be conveniently administered locally to the dermis and engineered in a way that is expected to prevent systemic side effects. The company is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis. This new study seeks to evaluate the effective dose and schedule of treatment to guide in-vivo animal studies planned for early 2024.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI